image
Healthcare - Drug Manufacturers - General - NYSE - US
$ 22.785
-4.15 %
$ 129 B
Market Cap
16.58
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one PFE stock under the worst case scenario is HIDDEN Compared to the current market price of 22.8 USD, Pfizer Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one PFE stock under the base case scenario is HIDDEN Compared to the current market price of 22.8 USD, Pfizer Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one PFE stock under the best case scenario is HIDDEN Compared to the current market price of 22.8 USD, Pfizer Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PFE

image
$27.0$27.0$26.0$26.0$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
63.6 B REVENUE
8.77%
14.9 B OPERATING INCOME
344.72%
8.05 B NET INCOME
270.67%
12.7 B OPERATING CASH FLOW
46.48%
2.65 B INVESTING CASH FLOW
108.22%
-17.1 B FINANCING CASH FLOW
-65.76%
13.7 B REVENUE
-22.79%
2.78 B OPERATING INCOME
-12.61%
2.97 B NET INCOME
621.90%
0 OPERATING CASH FLOW
0.00%
0 INVESTING CASH FLOW
100.00%
0 FINANCING CASH FLOW
100.00%
Balance Sheet Pfizer Inc.
image
Current Assets 50.4 B
Cash & Short-Term Investments 20.5 B
Receivables 14.8 B
Other Current Assets 15.1 B
Non-Current Assets 163 B
Long-Term Investments 2.23 B
PP&E 18.4 B
Other Non-Current Assets 142 B
9.60 %6.92 %7.08 %8.62 %66.74 %Total Assets$213.4b
Current Liabilities 43 B
Accounts Payable 5.63 B
Short-Term Debt 6.95 B
Other Current Liabilities 30.4 B
Non-Current Liabilities 81.9 B
Long-Term Debt 56.7 B
Other Non-Current Liabilities 25.2 B
4.51 %5.56 %24.35 %45.40 %20.18 %Total Liabilities$124.9b
EFFICIENCY
Earnings Waterfall Pfizer Inc.
image
Revenue 63.6 B
Cost Of Revenue 16.4 B
Gross Profit 47.2 B
Operating Expenses 25.6 B
Operating Income 14.9 B
Other Expenses 6.89 B
Net Income 8.05 B
70b70b60b60b50b50b40b40b30b30b20b20b10b10b0064b(16b)47b(26b)15b(7b)8bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
74.19% GROSS MARGIN
74.19%
23.48% OPERATING MARGIN
23.48%
12.62% NET MARGIN
12.62%
9.11% ROE
9.11%
3.76% ROA
3.76%
8.45% ROIC
8.45%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Pfizer Inc.
image
30b30b25b25b20b20b15b15b10b10b5b5b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 8.05 B
Depreciation & Amortization 7.01 B
Capital Expenditures -2.91 B
Stock-Based Compensation 877 M
Change in Working Capital -3.07 B
Others 891 M
Free Cash Flow 9.84 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Pfizer Inc.
image
Wall Street analysts predict an average 1-year price target for PFE of $32.1 , with forecasts ranging from a low of $24 to a high of $36 .
PFE Lowest Price Target Wall Street Target
24 USD 5.33%
PFE Average Price Target Wall Street Target
32.1 USD 40.84%
PFE Highest Price Target Wall Street Target
36 USD 58.00%
Price
Max Price Target
Min Price Target
Average Price Target
363634343232303028282626242422222020Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
1.70% DIVIDEND YIELD
0.43 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.801.801.601.601.401.401.201.201.001.000.800.800.600.600.400.400.200.200.000.000.280.30.320.340.360.380.390.40.410.420.430.280.30.320.340.360.380.390.40.410.420.430.280.30.320.340.360.380.390.40.410.420.281.120.31.200.321.280.341.360.361.440.381.520.391.560.41.600.411.640.421.680.862015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Pfizer Inc.
image
Sold
0-3 MONTHS
64.8 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
148 K USD 1
Bought
0 USD 0
0-3 MONTHS
499 K USD 1
3-6 MONTHS
28.2 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
New vaccine chief rocks pharmaceutical stocks CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump. youtube.com - 1 week ago
Build A 12%+ Yield On Cost By 2035 With May's Top 10 High-Yield Picks In this article, I present 10 attractive high-yield investment options for this month of May 2025, which not only offer dividend income but also potential for dividend growth. The selection process involves analyzing financial ratios, competitive advantages, valuations, and diversification across industries and countries to minimize risks and maximize returns. Highlighted top picks for May 2025 include VICI Properties, Chevron, Canadian Natural Resources, Pfizer, Altria, CVS Health, Toronto-Dominion Bank, Comcast, Vale, and Ares Capital. seekingalpha.com - 1 week ago
Pfizer Has Unreasonable Whiff Of The Marlboro Man What makes Pfizer and Altria alike? They have trouble keeping their customers. Altria's dividend yield is 7%, even as it trades at 11 times estimated earnings over the next 12 months – a 40% premium to Pfizer. Pfizer, meanwhile, continues to provide life-saving treatments, while its dealmaking at least offers hope of future breakthroughs. seekingalpha.com - 1 week ago
Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms President Donald Trump signed an executive order to incentivize drug manufacturing in the U.S. The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S. cnbc.com - 2 weeks ago
3 Dividend Stocks Under $100 To Buy This May With volatility taking center stage since the beginning of the year, investing in the stock market isn't as easy as it was. 247wallst.com - 2 weeks ago
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. zacks.com - 2 weeks ago
Top Wide-Moat Stocks to Invest in for Long-Term Growth Investing in wide-moat stocks like PFE, ASML, LRCX and KO can be a strategy for long-term wealth creation due to their ability to deliver consistent returns. zacks.com - 2 weeks ago
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold? Investors may stay invested in PFE stock to see how its new growth drivers perform. zacks.com - 2 weeks ago
2 Wonderful Dividends At Bargain Basement Prices Market pessimism creates opportunity. Pfizer and Rexford Industrial trade at historically low valuations, offering high dividend yields and strong long-term growth potential. Pfizer's diversified drug portfolio and promising oncology pipeline support its 7.1% yield and undervalued stock price. Rexford's focus on infill industrial properties in Southern California ensures steady growth. It's supported by a 5% yield and solid financials. seekingalpha.com - 2 weeks ago
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (May 2025) This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields about 3.74%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 9%. seekingalpha.com - 2 weeks ago
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (May 2025) Shares of Pfizer ( NYSE: PFE ) fell by 2.09% over the past month, compounding the stock's year-to-date troubles that have seen a slide of 9.11%. 247wallst.com - 2 weeks ago
Build Your Own ATM: 2 Undervalued Dividend Machines Yielding 7% Predicting markets is nearly impossible, even with perfect foresight; reactions can defy logic. That's why I focus on strategy, not headlines. Recessions are often declared late. By then, stocks may already be up. I prefer acting in fear, not waiting for official confirmation. Instead of chasing safety or volatility, I've picked two stocks that offer reliable income, strong business models, and long-term potential. seekingalpha.com - 2 weeks ago
8. Profile Summary

Pfizer Inc. PFE

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 129 B
Dividend Yield 1.70%
Description Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Contact 235 East 42nd Street, New York, NY, 10017 https://www.pfizer.com
IPO Date June 1, 1972
Employees 81000
Officers Dr. Chris Boshoff FMedSci, M.D., Ph.D. Chief Scientific Officer and President of Research & Development Mr. Douglas M. Lankler Executive Vice President & Chief Legal Officer Dr. Albert Bourla D.V.M., Ph.D. Chairman of the Board & Chief Executive Officer Ms. Jennifer B. Damico Senior Vice President, Controller & Principal Accounting Officer Dr. Michael S. Vincent M.D., Ph.D. Senior Vice President and Chief Scientific Officer of Inflammation & Immunology Ms. Payal Sahni Becher Chief People Experience Officer & Executive Vice President Ms. Sally M. Susman Executive Vice President & Chief Corporate Affairs Officer Ms. Lidia L. Fonseca Executive Vice President and Chief Digital & Technology Officer Ms. Francesca M. DeMartino Chief Investor Relations Officer Mr. David M. Denton Chief Financial Officer & Executive Vice President